{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:08:35Z","timestamp":1758474515003},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,7,11]],"date-time":"2016-07-11T00:00:00Z","timestamp":1468195200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s40261-016-0436-5","type":"journal-article","created":{"date-parts":[[2016,7,11]],"date-time":"2016-07-11T10:55:35Z","timestamp":1468234535000},"page":"857-862","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis"],"prefix":"10.1007","volume":"36","author":[{"given":"Domenico","family":"Acanfora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Acanfora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Scicchitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marialaura","family":"Longobardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Furgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Casucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Lanzillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Dentamaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annapaola","family":"Zito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele Antonelli","family":"Incalzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Matteo","family":"Ciccone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,11]]},"reference":[{"key":"436_CR1","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connoly","year":"2009","unstructured":"Connoly SJ, Yusuf S, Eikelboom J, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139\u201351.","journal-title":"N Engl J Med"},{"key":"436_CR2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391.","journal-title":"N Engl J Med"},{"key":"436_CR3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392.","journal-title":"N Engl J Med"},{"key":"436_CR4","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093\u20133014.","journal-title":"N Engl J Med"},{"key":"436_CR5","doi-asserted-by":"crossref","unstructured":"Bauersachs R, Berkowitz SD, et al.; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363(26):2499\u2013510.","DOI":"10.1056\/NEJMoa1007903"},{"key":"436_CR6","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342\u201352.","journal-title":"N Engl J Med."},{"key":"436_CR7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799\u2013808.","journal-title":"N Engl J Med."},{"issue":"369","key":"436_CR8","first-page":"1406","volume":"10","author":"HR B\u00fcller","year":"2013","unstructured":"B\u00fcller HR, D\u00e9cousus H, Hokusai-VTE Investigators, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thrombembolism. N Engl J Med. 2013;10(369):1406\u201315.","journal-title":"N Engl J Med."},{"key":"436_CR9","doi-asserted-by":"crossref","first-page":"e002322","DOI":"10.1161\/JAHA.115.002322","volume":"4","author":"IH Jaffer","year":"2015","unstructured":"Jaffer IH, Stafford AR, Fredenburgh JC, et al. Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation. J Am Heart Assoc. 2015;4:e002322.","journal-title":"J Am Heart Assoc."},{"issue":"369","key":"436_CR10","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","volume":"26","author":"JW Eikelboom","year":"2013","unstructured":"Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;26(369):1206\u201314.","journal-title":"N Engl J Med."},{"key":"436_CR11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1136\/heart.89.7.715","volume":"89","author":"H Oxenham","year":"2003","unstructured":"Oxenham H, Bloomfield P, Wheatley DJ, et al. Twenty year comparison of a Bjork\u2013Shiley mechanical heart valve with porcine bioprostheses. Heart. 2003;89:715\u201321.","journal-title":"Heart."},{"key":"436_CR12","doi-asserted-by":"crossref","first-page":"e576S","DOI":"10.1378\/chest.11-2305","volume":"141","author":"RP Whitlock","year":"2012","unstructured":"Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e576S\u2013600S.","journal-title":"Chest."},{"key":"436_CR13","doi-asserted-by":"publisher","unstructured":"Di Biase L, Trivedi C, Mohanty P, et al. Periprocedural and long term safety and feasibility of treatment with novel oral anticoagulants in patients with biological heart valve and atrial fibrillation (poster). J Am Coll Cardiol. 2015;65(10_S). doi: 10.1016\/S0735-1097(15)60355-2 .","DOI":"10.1016\/S0735-1097(15)60355-2"},{"key":"436_CR14","doi-asserted-by":"crossref","first-page":"17205","DOI":"10.1093\/europace\/euu178","volume":"16","author":"M Molteni","year":"2014","unstructured":"Molteni M, Plo FH, Primitz L, et al. The definition of valvular and non-valvular atrial fibrillation: results of a physicians\u2019 survey. Europace. 2014;16:17205.","journal-title":"Europace."},{"key":"436_CR15","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1093\/eurheartj\/ehu352","volume":"35","author":"R Caterina De","year":"2014","unstructured":"De Caterina R, Camm AJ. What is \u2018valvular\u2019 atrial fibrillation? A reappraisal. Eur Heart J. 2014;35:3328\u201335.","journal-title":"Eur Heart J."},{"key":"436_CR16","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"SJ Connolly","year":"2011","unstructured":"Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806\u201317.","journal-title":"N Engl J Med."},{"key":"436_CR17","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1093\/eurheartj\/ehu305","volume":"35","author":"G Breithardt","year":"2014","unstructured":"Breithardt G, Baumgartner H, Berkowitz SD, et al. Clinical characteristics and outcomes with rivaroxaban versus warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J. 2014;35:3377\u201385.","journal-title":"Eur Heart J."},{"key":"436_CR18","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.014807","volume":"132","author":"A Avezum","year":"2015","unstructured":"Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular hearty disease: finding from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2015;132:624\u201332.","journal-title":"Circulation."},{"key":"436_CR19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.echo.2010.12.008","volume":"24","author":"PS Douglas","year":"2011","unstructured":"Douglas PS, Garcia MJ, Haines DE, et al. ACCF\/ASE\/AHA\/ASNC\/HFSA\/HRS\/SCAI\/SCCM\/SCCT\/SCMR 2011 appropriate use criteria for echocardiography. A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echodardiography. J Am Soc Echocardiogr. 2011;24:229\u201367.","journal-title":"J Am Soc Echocardiogr."},{"key":"436_CR20","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/ejechocard\/jeq045","volume":"11","author":"M Pepi","year":"2010","unstructured":"Pepi M, Evangelista A, Nihoyannopoulos P, et al. Recommendations for echocardiography use in the diagnosis and management of cardiac sources of embolism: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur J Ecocardiogr. 2010;11:461\u201376.","journal-title":"Eur J Ecocardiogr."},{"key":"436_CR21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/europace\/eut083","volume":"15","author":"H Heidbuchel","year":"2013","unstructured":"Heidbuchel H, Verhamme P, Alings M, et al. European Hearth Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15:625\u201351.","journal-title":"Europace."},{"key":"436_CR22","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/j.ijcard.2012.07.019","volume":"167","author":"G Pasquale Di","year":"2013","unstructured":"Di Pasquale G, Mathieu G, Maggioni AP, et al. Current presentation and management of 7148 patients with atrial fibrillation in cardiology and internal medicine hospital centers: the ATA AF study. Int J Cardiol. 2013;167:2895\u2013903.","journal-title":"Int J Cardiol."},{"key":"436_CR23","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","volume":"17","author":"H Heidbuchel","year":"2015","unstructured":"Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467\u2013507.","journal-title":"Europace."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0436-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-016-0436-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0436-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T18:11:01Z","timestamp":1498327861000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-016-0436-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,11]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["436"],"URL":"https:\/\/doi.org\/10.1007\/s40261-016-0436-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,11]]}}}